Solid Tumors
Beginning of TNG260 and Pembrolizumab Study in Advanced Solid Tumors
SG Tylor
The first patient has received a dose of TNG260 in combination with pembrolizumab (Keytruda) as part of a Phase I/II ...
Results from Garsorasib Expand the Class of KRASG12C Inhibitors in NSCLC
SG Tylor
Early findings from the use of garsorasib (D-1553), an oral KRASG12C inhibitor, in patients with advanced non–small cell lung cancer ...
ASCO 2023: Promising Results from Sleeping Beauty TCR-T Cells
SG Tylor
ABSTRACT NUMBER – 2547 Alaunos’ Clinical TCR Library focuses on targeting the most common mutations found in KRAS, TP53, and ...
